Additional prognostic value of toe-brachial index beyond ankle-brachial index in hemodialysis patients.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
20 08 2020
Historique:
received: 10 02 2020
accepted: 29 07 2020
entrez: 22 8 2020
pubmed: 21 8 2020
medline: 21 10 2021
Statut: epublish

Résumé

Ankle-brachial index (ABI), the first-line diagnostic test for peripheral artery disease, can be falsely elevated when ankle arteries are incompressible, showing a J-shaped association with mortality. In this situation, toe-brachial index (TBI) is the recommended test. However, whether TBI provides additional prognostic information beyond ABI in patients on hemodialysis is unknown. In this retrospective cohort study of 247 Japanese prevalent hemodialysis patients (mean age 66.8 [SD 11.6] years), we evaluated mortality (116 deaths over a median follow-up of 5.2 years) related to quartiles of ABI and TBI, as well as three categories of low ABI (≤0.9), normal/high ABI (> 0.9) + low TBI (≤0.6), and normal/high ABI + normal TBI (> 0.6) using multivariable Cox models. ABI showed a J-shaped association with mortality (adjusted hazard ratio 2.72 [95% CI, 1.52-4.88] in the lowest quartile and 1.59 [95% CI, 0.87-2.90] in the highest quartile vs. the second highest). Lower TBI showed a potentially dose-response association with mortality (e.g., adjusted hazard ratios 2.63 [95% CI, 1.36-5.12] and 2.89 [95% CI, 1.49-5.61] in the lowest two quartiles vs. the highest). When three categories by both ABI and TBI were analyzed, those with low ABI (≤0.9) experienced the highest risk followed by normal/high ABI (> 0.9) + low TBI (≤0.6). Among patients with normal/high ABI (> 0.9), the increased mortality risk in individuals with low TBI (≤0.6) compared to those with normal TBI (> 0.6) were significant (adjusted hazard ratio 1.84 [95% CI, 1.12-3.02]). Lower TBI was independently associated with mortality in patients on hemodialysis and has the potential to classify mortality risk in patients with normal/high ABI. Our results support the importance of evaluating TBI in addition to ABI in this clinical population.

Sections du résumé

BACKGROUND
Ankle-brachial index (ABI), the first-line diagnostic test for peripheral artery disease, can be falsely elevated when ankle arteries are incompressible, showing a J-shaped association with mortality. In this situation, toe-brachial index (TBI) is the recommended test. However, whether TBI provides additional prognostic information beyond ABI in patients on hemodialysis is unknown.
METHODS
In this retrospective cohort study of 247 Japanese prevalent hemodialysis patients (mean age 66.8 [SD 11.6] years), we evaluated mortality (116 deaths over a median follow-up of 5.2 years) related to quartiles of ABI and TBI, as well as three categories of low ABI (≤0.9), normal/high ABI (> 0.9) + low TBI (≤0.6), and normal/high ABI + normal TBI (> 0.6) using multivariable Cox models.
RESULTS
ABI showed a J-shaped association with mortality (adjusted hazard ratio 2.72 [95% CI, 1.52-4.88] in the lowest quartile and 1.59 [95% CI, 0.87-2.90] in the highest quartile vs. the second highest). Lower TBI showed a potentially dose-response association with mortality (e.g., adjusted hazard ratios 2.63 [95% CI, 1.36-5.12] and 2.89 [95% CI, 1.49-5.61] in the lowest two quartiles vs. the highest). When three categories by both ABI and TBI were analyzed, those with low ABI (≤0.9) experienced the highest risk followed by normal/high ABI (> 0.9) + low TBI (≤0.6). Among patients with normal/high ABI (> 0.9), the increased mortality risk in individuals with low TBI (≤0.6) compared to those with normal TBI (> 0.6) were significant (adjusted hazard ratio 1.84 [95% CI, 1.12-3.02]).
CONCLUSIONS
Lower TBI was independently associated with mortality in patients on hemodialysis and has the potential to classify mortality risk in patients with normal/high ABI. Our results support the importance of evaluating TBI in addition to ABI in this clinical population.

Identifiants

pubmed: 32819299
doi: 10.1186/s12882-020-01991-7
pii: 10.1186/s12882-020-01991-7
pmc: PMC7439547
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

353

Références

Am J Nephrol. 2008;28(2):339-46
pubmed: 18046081
Eur Heart J. 2011 Nov;32(22):2851-906
pubmed: 21873417
Am J Kidney Dis. 2014 Dec;64(6):954-61
pubmed: 25266479
Circulation. 2004 Jan 27;109(3):320-3
pubmed: 14732743
Diabetes Care. 1981 Mar-Apr;4(2):289-92
pubmed: 7215085
Kidney Med. 2020 Jan 08;2(1):68-75
pubmed: 32734227
J Am Coll Cardiol. 2017 Mar 21;69(11):1465-1508
pubmed: 27851991
J Vasc Surg. 2007 Jan;45 Suppl S:S5-67
pubmed: 17223489
Hemodial Int. 2019 Apr;23(2):214-222
pubmed: 30734987
Ther Apher Dial. 2009 Apr;13(2):103-7
pubmed: 19379148
Eur J Vasc Endovasc Surg. 2010 Mar;39(3):316-22
pubmed: 20089422
Diabetologia. 1988 Jan;31(1):16-23
pubmed: 3350219
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1809-1816
pubmed: 27445162
Diabetologia. 1993 Jul;36(7):615-21
pubmed: 8359578
Angiology. 2015 Nov;66(10):911-7
pubmed: 25694516
Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
pubmed: 17140820
JAMA. 2008 Jul 9;300(2):197-208
pubmed: 18612117
Kidney Int. 2017 Jan;91(1):227-234
pubmed: 27884399
J Vasc Surg. 2015 Mar;61(3 Suppl):2S-41S
pubmed: 25638515
J Vasc Surg. 2014 Aug;60(2):390-5
pubmed: 24657294
J Am Soc Nephrol. 2007 Feb;18(2):629-36
pubmed: 17215445
Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33
pubmed: 31182334
Diabetes Care. 2009 Apr;32(4):e44
pubmed: 19336632
Lancet Diabetes Endocrinol. 2017 Sep;5(9):718-728
pubmed: 28716631
Circulation. 2004 Feb 17;109(6):733-9
pubmed: 14970108
J Am Soc Nephrol. 2005 Feb;16(2):514-9
pubmed: 15601746
BMC Med Res Methodol. 2017 Jan 9;17(1):2
pubmed: 28068910
Eur J Vasc Endovasc Surg. 2018 Mar;55(3):301-302
pubmed: 29579461

Auteurs

Manabu Hishida (M)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Suite 2-600, Baltimore, MD, 21287, USA.
Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Takahiro Imaizumi (T)

Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Steven Menez (S)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Suite 2-600, Baltimore, MD, 21287, USA.
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.

Masaki Okazaki (M)

Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Shin'ichi Akiyama (S)

Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Hirotake Kasuga (H)

Kaikoukai Healthcare Group Kaikoukai Central Clinic, Nagoya, Japan.

Junichi Ishigami (J)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Suite 2-600, Baltimore, MD, 21287, USA.

Shoichi Maruyama (S)

Department of Nephrology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Kunihiro Matsushita (K)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 2024 E. Monument Street, Suite 2-600, Baltimore, MD, 21287, USA. kmatsus5@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH